Dose Intensification of Etoposide in the BEAM ABMT Protocol for Malignant Lymphoma

References

• Linch D. C., Winfield D., Goldstone A. H., et al. Dose intensification is effective in relapsed or resistant Hodgkin's Disease: Results of the BNLI randomised study. Lancet. 1993; 341: 138–142
   PubMedGoogle Scholar
• Chopra R., Linch D. C., McMillan A. K., et al. MiniBEAM plus BEAM ABMT as salvage treatment for very poor prognosis Hodgkin's Disease. Br. J. Haem. 1991; 77(Suppl 1)20
   Google Scholar
• Pusey W. A. Cases of sarcoma and of Hodgkin's disease treated by exposure to X rays: A preliminary report. JAMA 1902; 38: 166
   Google Scholar
• Kaplan H. S. Hodgkin's disease Biology, treatment and prognosis. Blood 1981; 57: 813
   PubMed Web of Science ®Google Scholar
• De Vila V. T., Simon R. M., Hubbard S. M., et al. Curability of advanced Hodgkin's Disease with chemotherapy: Long term follow up of MOPP treated patients at the NCI. Ann. Intern. Med. 1980; 92: 587–595
   PubMed Web of Science ®Google Scholar
• De Vita V. T., Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin' s disease. Ann. Intern. Med 1970; 78: 881
   Google Scholar
• Longo D. L., Young R. C., Wesley M., et al. Twenty years of MOPP chemotherapy for Hodgkin's disease. J. Clin. Oncol. 1986; 4: 1295
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J. M. An update of the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABVD hybrid program. Sent, in Haematol. 1988; 25: 34
   Google Scholar
• Cannellos G. P., Anderson J. R., Propert K. J., et al. Chemotherapy of advanced Hodgkin's Disease with MOPP, ABVD or MOPP alternating with ABVD. N. Eng. J. Med. 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Goldstone A. H., Linch D. C. Bone marrow transplantation in the malignant lymphomas. Recent Advances in Haematology, A. V. Hoffbrand, M. K. Brenner. Churchill Livingstone. 1992
   Google Scholar
• Tannir N., Hagemeister F., Velasques W., et al. Longterm followup with ABDIC salvage chemotherapy of MOPP resistant Hodgkin's disease. J. Clin. Oncol. 1983; 1: 432
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonfante V., Bonadonna G. Salvage chemotherapy with ABVD in MOPP resistant Hodgkin's disease. Ann. Intern. Med. 1982; 96: 139
   PubMed Web of Science ®Google Scholar
• Longo D. L., Duffey P. L., Young R. C., et al. Conventional dose salvage chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J. Clin. Oncol. 1991; 10: 210
   Web of Science ®Google Scholar
• Viviani S., Santoro A., Negretti E., et al. Salvage chemotherapy in Hodgkin's disease. Ann. Oncol. 1990; 1: 123
   PubMed Web of Science ®Google Scholar
• Gore M. E., McElwain T. J. Lymphomas: the impact of chemotherapy on survival. Cancer Surv. 1989; 8(3)647–670
   PubMedGoogle Scholar
• Weick J., Dahlberg S., Miller T., et al. The treatment of Non Hodgkin's lymphoma with m-BACOD, ProMACE-CytaBOM and MACOP-B: The Southwest Oncology Group (SWOG) Experience. Proceedings of ASCO, San Francisco, 1989; 254, 8, Abstract 990
   Google Scholar
• Vose J. M., Armitage J. O. The present status of therapy for patients with aggressive Non Hodgkin's Lymphoma. Ann. Oncol. 1991; 2(suppl 2)171–176
   PubMedGoogle Scholar
• Armitage J. O. Drug therapy: Treatment of Non Hodgkin's Lymphoma. New. Engl. J. Med. 1993; 328(14): 1023–1030
   Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced nonhodgkin's lymphoma. N. Eng. J. Med. 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Jones J. M. Advances in the treatment of Non Hodgkin's Lymphoma. J. Med. Assoc. Ga. 1989; 78(2)105–108
   PubMedGoogle Scholar
• Soiffer R. J., Caliguiri M. A., Tondini C., Canellos G. P. High dose cytosine in relapsed and refractory Non Hodgkin's Lymphoma: limited role as a single agent. Cancer 1989; 74(7)2579–2584, 15
   Google Scholar
• De Lord C., Newland A. C., Linch D. C., Vaughan-Hudson B., Vaughan-Hudson G. Failure of IM VP16 as second line treatment for relapsed or refractory high grade Non Hodgkin's Lymphoma. Haemal. Oncol. 1992; 10: 81–86
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabinills P., Salvador P. Effective salvage therapy for lymphoma with cisplatin in combination with high dose AraC and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Cabinillas F. Experience with ifosphamide combinations in malignant lymphomas. Sent. Oncol. 1989; 16(1)78–81
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Vose J. M., Bierman P. J. Salvage therapy for patients with Non Hodgkin's Lymphoma. Monogr Natl Cancer Inst. 1990; 10: 39–43
   PubMedGoogle Scholar
• Goldie J. H., Coldman A. J. A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treatment Reports 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Skipper H. E. Criteria associated with the destruction of leukaemia and solid tumor cells in animals. Cancer Res. 1967; 27(1)2636–2645
   PubMedGoogle Scholar
• Hryniuk W. M. The importance of dose intensity on the outcome of chemotherapy. Important Advances in Oncology, V. T. De Vita, S. Hellman, S. A. Rosenberg. J. B. Lippencott, Philadelphia 1990; 121–142
   Google Scholar
• Lepage E., Gisselbrecht C., Haioun C., Sebban C., Bosly A., Tilly H., Morel P., Herbrecht R., Reyes F., Coiffier B. Relative received dose intensity in poor risk lymphoma patients: higher Dl correlates with longer survival. Blood 1992; 80(10)158, suppl 1
   Google Scholar
• Gribben J. G., Vaughan-Hudson B., Linch D. C. The potential value of therapy with autologous bone marrow rescue in the treatment of the malignant lymphomas. Haematol. Oncol. 1987; 5: 281–286
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Wolf S. N., Herzig R. H., et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086
   PubMed Web of Science ®Google Scholar
• Peterson F. B., Appelbaum F. R., Hill R., et al. Autologous bone marrow transplantation for malignant lymphoma: A report of one hundred and one cases from Seattle. J. Clin. Oncol. 1990; 8: 638
   PubMed Web of Science ®Google Scholar
• McMillan A. K., Goldstone A. H., Linch D. C. One hundred cases of relapsed Hodgkin's disease treated with BEAM chemotherapy in a single centre. Proceedings of the Fourth International Conference on Malignant Lymphomas. 1990; 22
   Google Scholar
• Jones R. J., Piantadosi S., Mann R. B., et al. High dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's Disease. J. Clin. Oncol 1990; 8: 527–537
   PubMed Web of Science ®Google Scholar
• Phillip T., Hartman O., Biron P., Cahn J. Y., Pein F., Bordigoni P., Soullet G., Gartner M., Lasset C., Chauvin F. High dose therapy and autologous bone marrow transplantation in partial remission after first line induction therapy fordiffuse Non Hodgkin's Lymphoma. J. Clin. Oncol. 1988; 6(7)1118–1124
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Takvorian T., Anderson K. C., Mauch P., Rabinowe S. N., Blake K., et al. Autologous bone marrow transplantation in B-cell Non Hodgkin's Lymphoma: very low treatment related mortality in 100 patients in sensitive relapse. J. Clin. Oncol 1990; 8(5)784–791
   PubMed Web of Science ®Google Scholar
• Coser P., Santini G., Rizzoli V., Porcellini A., Chisesi T., Sertoli R., Contu A., et al. Autologous bone marrow transplantation (ABMT) in poor prognosis diffuse Non Hodgkin's Lymphoma: Report of the Non Hodgkin's Lymphoma Cooperative Study Group. Bone Marrow Transplant. 1989; 4(suppl 4)164–175
   PubMedGoogle Scholar
• Armitage J. O. Autologous bone marrow transplantation for patients with aggressive Non Hodgkin's Lymphoma. Bone Marrow Transplant. 1992; 10(suppl 1)62–63
   PubMedGoogle Scholar
• Vose J. M., Armitage J. O., Bierman P. J., Weisenberger D. D., Hitchins M., Dowling M. D., et al. Salvage therapy for relapsed or refractory Non Hodgkin's Lymphoma utilising autologous bone marrow transplantation. Am. J. Med. 1989; 87(3)285–288
   PubMed Web of Science ®Google Scholar
• Tura S., Zinzani P. L., Mazza P., Boccia M., Gherlinzoni F., Pileri S., Amadori S., et al. ABMT vs DHAP in residual disease following third generation regimens for aggressive Non Hodgkin's Lymphomas. Blood 1992; 80(10)157, suppl 1
   Google Scholar
• Gianni A. M., Bregni S., Sienna S., Brambilla C., Lombardi F., Gandola C., Tarella A., Stern P., Valagussa P., Bonnadonna G. Prospective randomised study of MACOP-B vs rhGM-CSF supported high dose sequential myeloablative chemoradiotherapy in diffuse large cell lymphomas. Proceedings of ASCO 1991; 10: 274, (abstr)
   Google Scholar
• Wheeler C., Antin J. H., Churchill W. H., et al. Cyclophosphamide, carmustine and etoposide with ABMT in refractory Hodgkin's disease and Non Hodgkin's Lymphoma: A dose finding study. J. Clin. Oncol 1990; 8: 648
   PubMed Web of Science ®Google Scholar
• Zulian G. B., Selby P., Milan S. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br. J. Cancer 1989; 59: 631
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Shepard J. D., Barnett M. J., Lansdorp P. M., Klingeman H. C., Spinelli J. J., Nevill T. J., Chan K. W., Reece D. E. Busulphan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in haematolog-ical malignancy. J. Clin. Oncol 1991; 9(10)1880–1888
   PubMed Web of Science ®Google Scholar
• Bearman S. I., Applebaum F. R., Buckner C. D., Petersen F. B., Fisher L. B., et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol 1988; 6: 1562–1568
   PubMed Web of Science ®Google Scholar
• Cowen D., Richaud P., Marit G., Cony-Makhoul P., Trouette R., Faberes C., Reiffers J. Regimen related toxicity in patients undergoing bone marrow transplantation with total body irradiation using a sweeping beam technique. Bone Marrow Transplant. 1992; 10: 515–519
   PubMed Web of Science ®Google Scholar
• Carella A. M., Carlier P., Congui A., et al. Autologous bone marrow transplantation as an adjuvant therapy of high risk Hodgkin's disease patients in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant. 1991; 8: 31–35
   Google Scholar
• Jaganath S., Armitage J. O., Dicke K. A., et al. Prognostic indicators after high dose cyclophoshamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's Disease. J. Clin. Oncol 1989; 7: 179–185
   PubMed Web of Science ®Google Scholar
• Khwaja A., Mills W., Leveridge K., et al. Efficacy of delayed Granulocyte colony stimulating factor after autologous bone marrow transplantation. Bone Marrow Transplant. 1993; 11: 479–482
   PubMed Web of Science ®Google Scholar
• Goldstone A. H., Kwaja A. K. The role of haematopoeitic growth factors in bone marrow transplantation. Leuk. Res. 1990; 14: 721
   PubMed Web of Science ®Google Scholar
• Sheridan W. P., Morstyn G., Wolf, et al. Granulocyte colony stinulating factor and recovery after high dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–895
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Linch D. C., Goldstone A. H., et al. High dose chemotherapy and ABMT in NHL is successful only in those patients who have disease that is responsive to conventional dose therapy. J. Clin. Oncol 1989; 7: 1621–1629
   PubMed Web of Science ®Google Scholar